JNJ-39393406 clinical trials
Also written JNJ-39393406.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses JNJ-39393406 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2009 | 3 |
| 2010 | 1 |
| 2014 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3) · Tangent Data (1) · K.N. Roy Chengappa (1) · Chengappa, K.N. Roy, MD (1) · Janssen Pharmaceutica N.V., Belgium (1)
Studies
Open first, then newest update. How each study uses JNJ-39393406 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- The Effects of JNJ-39393406 on Psychometric Performance and Residual DepressiveCompletedPhase 2Tangent DataNCT02677207Written as JNJ-39393406How we know
- Novel Smoking Cessation Drug for SchizophreniaCompletedPhase 2K.N. Roy ChengappaNCT02230384Written as Active JNJ DrugHow we know
- Test of Novel Drug for Smoking CessationCompletedPhase 2Chengappa, K.N. Roy, MDNCT02217527Written as Active JNJ DrugHow we know
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy ParticipantsCompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT02023255Written as JNJ-39393406How we know
- A Study of Solid Formulations of JNJ-39393406 in Healthy Male ParticipantsCompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01986491Written as JNJ 39393406 30 mg solid XHow we know
- A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy VolunteersCompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01556217Written as JNJ-39393406How we know
- The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic PatientsTerminatedPhase 1Janssen Pharmaceutica N.V., BelgiumNCT01137799Written as JNJ-39393406How we know
Codes
What other systems call JNJ-39393406 · ClinicalTrials.gg INT001061
- MeSH (NLM) C000630150JNJ-39393406One source NLM
- UNII (FDA) T930SOU82PJNJ-39393406Confirmed NLM, Wikidata
- Wikidata Q27289838JNJ-39393406Confirmed NLM, Wikidata
- DrugBank DB11867One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630150 | JNJ-39393406 | One source NLM |
| UNII (FDA) | T930SOU82P | JNJ-39393406 | Confirmed NLM, Wikidata |
| Wikidata | Q27289838 | JNJ-39393406 | Confirmed NLM, Wikidata |
| DrugBank | DB11867 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.